Biotechnology · Healthcare
Chief Accounting Officer
2022-12-12–present
Chief Accounting Officer
Gain Therapeutics, Inc. (GANX)Equibles does not estimate personal net worth.
Get an email with a short summary when Gain Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get GANX alertsGianluca Fuggetta is recorded as Chief Accounting Officer at Gain Therapeutics, Inc. (GANX) since December 12, 2022. Gain Therapeutics, Inc. reported in an 8-K filed September 28, 2026 that Gianluca Fuggetta resigned as Senior Vice President of Finance, principal financial officer, and principal accounting officer, effective September 30, 2026. Gain Therapeutics, Inc. reported in an 8-K filed January 7, 2025 that Gianluca Fuggetta was appointed Senior Vice President, Finance and Principal Financial Officer, effective January 6, 2025. Gain Therapeutics, Inc. reported in an 8-K filed December 16, 2022 that Gianluca Fuggetta was appointed Principal Accounting Officer, effective December 12, 2022. Gain Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Gain Therapeutics, Inc. includes Gene Mack (CEO, CFO and Board Member), Gene Mack, MBA (CEO, CFO and Board Member), Matthias Alder (CEO, COO and Board Member) and 3 others.
“On September 22, 2026, Gianluca Fuggetta, Senior Vice President of Finance, principal financial officer, and principal accounting officer of Gain Therapeutics, Inc. (the "Company"), notified the Company of his intention to resign from his positions with the Company, with such resignation to be effective September 30, 2026, in order to pursue other opportunities.”
“on January 6, 2025, the Board of Directors appointed Gianluca Fuggetta, the Company’s current Vice President of Finance and Principal Accounting Officer, as the Company’s Senior Vice President, Finance and the Company’s Principal Financial Officer.”
2022-12-12–present
Proxy statement
Start not stated–present
Last confirmed April 28, 2026
2025-01-06–2026-09-30
Biotechnology · Healthcare
Chief Accounting Officer
2022-12-12–present